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In artificial gene delivery, messenger RNA (mRNA) is an attractive alternative to plasmid DNA (pDNA) since it does not require transfer into the
cell nucleus. Here we show that, unlike for pDNA transfection, the delivery statistics and dynamics of mRNA-mediated expression are generic and
predictable in terms ofmathematicalmodeling.Wemeasured the single-cell expression time-courses and levels of enhanced green fluorescent protein
(eGFP) using time-lapse microscopy and flow cytometry (FC). The single-cell analysis provides direct access to the distribution of onset times, life
times and expression rates of mRNA and eGFP. We introduce a two-step stochastic delivery model that reproduces the number distribution of
successfully delivered and translated mRNA molecules and thereby the dose–response relation. Our results establish a statistical framework for
mRNA transfection and as such should advance the development of RNA carriers and small interfering/micro RNA-based drugs.
From the Clinical Editor: This team of authors established a statistical framework formRNA transfection by using a two-step stochastic delivery
model that reproduces the number distribution of successfully delivered and translated mRNAmolecules and thereby their dose-response relation.
This study establishes a nice connection between theory and experimental planning and will aid the cellular delivery of mRNA molecules.
© 2014 The Authors. Published by Elsevier Inc.
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Open access under CC BY-NC-SA license.Nucleic acid transfer is widely used in basic research as well as
biomedical applications. In recent years, novel stabilized mRNA
constructs have becomemore prevalent in therapeutic applications
showing superior properties compared to plasmid DNA.1–3 This
progress is mostly due to the discovery of 5′ mRNA anti-reverse
cap analogues (ARCA), to the insertion of additional untranslated
regions, and to poly(A) tails that significantly promote and prolong
efficient translation of foreign mRNA inside cells.4–10 In general,
mRNA delivery has considerable advantages over pDNA delivery
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Open access under CCtransfer into the nucleus and hence mRNA transfection is also
effective in non-dividing cells, which is a major drawback of
pDNA transfection.11–13 This makes mRNA a particularly strong
therapeutic agent in dendritic cells which are otherwise hard to
transfect.14–16 Secondly, immunogenic response to mRNA
activated by Toll-like receptors (specifically TLR3) is less
pronounced compared to unmethylated CpG motifs of DNA
recognized by TLR9.2,9,17,18 In addition, mRNA transfection
remains transient, preventing the risk of permanently integrating
into the genome. Hence, mRNA delivery is of increasing interest
for future biomedical applications in particular with regards to
strategies that aim to use mRNA as a programmable device for
controlled intracellular mRNA targeting and in situ logic
evaluation of disease-related conditions.19–24
The major hurdle to clinical trials remains the delivery of
nucleic acid to eukaryotic cells. As a result, an ongoing search is
still underway for non-viral delivery methods that are optimized
for efficient and controlled delivery of mRNA. Since the first
non-viral delivery of mRNA using cationic lipids by Malone,
Felgner and Verma,25 many synthetic delivery systems were
found to be effective for mRNA delivery, with generally better
efficiency found for liposomes than for polyplexes.26–31 It istudies: Delivery, kinetics and statistics by numbers. Nanomedicine: NBM
 BY-NC-SA license.
Figure 1. Comparison of mRNA and pDNA Vectors (both gene vectors encoding for the same eGFP protein) and their respective uptake pathways. (A)
Linearized RNA (1192 bases) furnished with a stabilizing CAP sequence, an enhancing UTR sequence, and poly-(A) tail. (B) pDNA (4733 base pairs) under the
control of the CMV promoter. The vector transfer under identical transfection protocols differs because mRNA is translated after endosomal escape, while
plasmid DNA must be transferred into the nucleus for the initiation of transcription.
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translocated via endosomal uptake, cytosolic release and - in case
of pDNA - nuclear entry. However, mechanistic insights are
mostly limited to assessment of changes in the transfection
efficiency as a function of biochemical or structural variations of
the carrier. A full pharmacokinetic model, which in principle has
been established using compartment models and rate
equations,32–34 lacks validation due to the multitude of kinetic
rates. In comparative studies, it was shown that mRNA
transfection compared to pDNA transfection is faster and yields
a larger fraction of transfected cells.27,35 However, a more
detailed and quantitative understanding in particular of artificial
mRNA delivery is of increasing importance for gaining a
systems-level description of the kinetics of RNA-based
devices.21,24,36 The degree of predictive power describing
synthetic RNA expression level and timing will nevertheless
depend on the degree of accuracy with which the transfer
efficiency and transfer kinetics can be described. Moreover,
predictive modeling of mRNA transfection will be instrumental
for the advancement of mRNA based therapies. Yet, any non-
viral delivery is inherently stochastic and the expression level
and timing of every single cell is different. Hence, measurements
at the single-cell level and analysis of the corresponding
distribution functions are necessary to acquire the true
population response in transfection experiments. Using single-
cell analysis, we recently showed that in the case of pDNA
transfection, the distribution of gene expression levels can be
reproduced using a stochastic model.37 Similarly, a recent
statistical analysis of nanoparticle dosing exhibited Poisson-type
distribution in the number of nanoparticles being taken up.38
Here, we study gene expression after non-viral delivery of
synthetic mRNA analyzing single-cell expression traces in terms
of numbers of complexes delivered and numbers of proteins
being expressed. Using single-cell fluorescence time-lapse
imaging and FC, we monitored expression of a cap-stabilizedmRNA vector encoding for eGFP. Single-cell fluorescence time-
courses were fitted based on rate equations for translation and
mRNA/eGFP degradation yielding the onset time distribution,
mRNA/eGFP degradation rates, and the expression rate. The
mRNA expression model applies to at least three different cell
lines. We interpret the cell-to-cell variability in eGFP levels, i.e.
the distribution of expression rates, in terms of number of
successfully delivered and translated mRNA. The latter is
estimated using a two-step stochastic delivery model. The model
assumes delivery of mRNA in finite size complexes that are
taken up stochastically by endosomes and randomly released
from endosomes into the cytosol. The model quantitatively
reproduces the dose–response relation and yields the correct
shape of the distribution function. As such, this work represents
an advance in predictive modeling of mRNA transfection for
quantitative gene expression studies, which we believe will be
particularly useful for research on siRNA and miRNA kinetics.Methods
pDNA and mRNA-vectors
Two different vectors for pDNA and mRNA transfection
were designed. The peGFP-N1-Vector (commercially available
at BD Biosciences Clontech, Germany, 4733 base pairs) is the
standard eGFP vector. As an mRNA reference construct for in
vitro transcription, we designed a vector that is based on the
pSTI-A120-vector (4746 base pairs, transcript 1192 bases),
which has previously been described in literature.10 The
complete vector map is presented in Figure S1. Both vectors
contain the same eGFP gene but differ in their promoter region:
The peGFP-N1-Vector has a strong CMV-promoter for
expression in vitro. The mRNA is generated with a commercial
in vitro transcription kit from the pSTI-A120-vector under the
control of the T7 promoter. The backbone of both vectors is
Figure 2. Representative FC scatter plots for mRNA- and pDNA- mediated eGFP expression in three different cell lines (arbitrary units). (A-F) Two-dimensional
scatterplots (sideward scatter vs. fluorescence intensity) for HeLa, A549 and MDCKII cells 25 h post-transfection with mRNA and pDNA. (G-I) Average
fluorescence intensity per fluorescent cell (RNA data are shown in blue, DNA data are shown in red); (J-L) Percentage of fluorescent cells (mean ± SD).
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poly(A) tail and a 3′ untranslated region (UTR) from human
β-globin enabling in vitro transcription of polyadenylated RNA.
To generate in vitro-transcribed mRNA (IVT RNA), the
plasmid is linearized downstream of the poly(A) tract by SapI
digestion and purified by phenol/chloroform extraction and
sodium acetate precipitation. One μg of the linearized vector is
used as a template for the in vitro transcription reaction using the
Biozym Kit (MessageMAX™ T7 ARCA-Capped Message
Transcription Kit). Having an Anti-Reverse Cap Analog
(ARCA) (m2
7, 3′-OG[5′]ppp[5′]G) cap on the 5′ end, ARCA
cannot be incorporated in the reverse orientation. Thus, 100% of
the caps in the produced IVT RNA are in the correct orientation,
increasing the translation efficiency of the IVT RNA.10,39Materials
FBS, Leibovitz's L-15 Medium (Gibco), Lipofecta-
mine™2000, OptiMEM (Gibco) and Sybr Gold were purchasedfrom Invitrogen, Germany. Syto RNAselect was purchased from
Life Technologies, Germany. 6-well culture plates (Falcon) were
purchased from VWR International GmbH, Germany. Sterile
PBS was prepared in-house. Ham's F-12K, MEM, DMEM and
Trypsin-EDTA were purchased from c.c.pro GmbH, Germany.
Cell culture
Ahuman alveolar adenocarcinoma cell line (A549,ATCCCCL-
185) was grown in Ham’s F12K medium supplemented with 10%
FBS. HeLa cells (ATCC CCL-2) were cultured using minimum
essential medium (MEM) with Earle's salts and L-Glutamine
supplemented with 10% fetal bovine serum (FBS). AMadin-Darby
Canine Kidney epithelial cell line (MDCKII, ATCC CCL-34) was
cultured in DMEM with 4,5 g/L glucose and 110 mg/L pyruvate,
supplemented with 10% fetal bovine serum. All cell lines were
grown in a humidified atmosphere at 5% CO2 level.
Transfection
The cells were transfected with equimolar amounts of pDNA
and mRNA for FCmeasurements and with equal weight amounts
Figure 3. mRNA- and pDNA-mediated gene expression kinetics. (A, B) Exemplary images of an average transfection of A549 cells 25 h post-transfection
(overlay of bright field and eGFP fluorescence image. Scale bars 100 μm). (C, D) Representative fluorescence time-courses of eGFP gene expression after
transfection with mRNA (C) and pDNA (D). To highlight the characteristic differences, we chose and color-labeled three exemplary time-courses each. mRNA
expression shows early onset and continuous rise in the eGFP level, while pDNA expression exhibits delayed onsets and S-shape expression time-courses.
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Supplementary). The same transfection reagent (Lipofecta-
mine2000®) and the same standard transfection protocols were
used for pDNA and mRNA delivery. For transfection with
fluorescently labelled mRNA, we followed the standard pro-
tocols for labelling mRNA with Sybr Gold/Syto RNAselect and
prepared lipoplexes with labelled mRNA.
Data acquisition and quantitative image analysis
Live-cell imaging was performed on a motorized inverted
microscope (Nikon, Eclipse Ti-E) equipped with an objective
lens (CFI PlanFluor DL-10×, Phase1, N.A. 0.30; Nikon) and
with a temperature-controlled mounting frame for the micro-
scope stage. To acquire cell images, we used a cooled CCD
camera (CLARA-E, Andor). A mercury light source (C-HGFIE
Intensilight, Nikon) was used for illumination and a filter cube
with the filter set 41024 (Chroma Technology Corp., BP450-
490, FT510, LP510-565) was used for eGFP detection. An
illumination shutter control was used to prevent bleaching.
Images were taken at 10 fold magnification with a constant
exposure time of 1300 ms at 10-minute intervals for at least
25 hours post-transfection. Fluorescence images were consoli-
dated into single-image sequence files. Negative control images
were taken to assess lamp threshold values and were subtracted
from corresponding image sequence files to eliminate auto-
fluorescence effects. Using SINGLECELLTRACKER, an in-house-
development software based on ImageJ,40 fluorescence intensities
were integrated over cell contours and corrected for background
noise. The software calculates the cells’ fluorescence over the
entire sequence and connects corresponding intensities to time-
courses of the fluorescence per cell.eGFP quantification and calibration
To calculate numbers of eGFP molecules from grey values of
the recorded time-lapse movies, a calibration-channel system
was developed. Micro channels of known dimensions were filled
with eGFP solutions of defined concentrations. Images of the
channels were taken under the same experimental conditions as
the monitored expression kinetics data, corrected for background
and analysed to get calibration curves. For a detailed description
of the calibration method, see Supplementary.
Flow cytometry
eGFP fluorescence intensity in cells was measured by FC
(Partec, CyFlow space). Flow cytometer settings were adjusted
to discriminate transfected and non-transfected cells. The
Windows™ FloMax® software package was used for data
analysis. See Supplementary for additional information.Results
mRNA vs. pDNA transfection
In a first set of experiments, mRNA-mediated transfection
was quantified using FC and compared to pDNA-mediated
transfection as a reference. As schematically depicted in Figure 1,
the design of the mRNA vector (Figure 1, A) was chosen for
maximal analogy to the pDNA vector. The pDNA vector is a
commercial eGFP plasmid equipped with a CMV promoter
(Figure 1, B). The mRNA construct consists of polyadenylated
RNAs enabling in vitro transcription under the control of the T7-
promoter and contains 2 sequential human β-globin 3′UTRs as
well as the anti-reverse cap analog (ARCA) (see also Methods,
Figure 4. Single-cell mRNA translation, analyzed by a kinetic rate model. (A)
Time-courses of eGFP expression after mRNA transfection (gray lines). Blue
lines are fits according to the rate equation model (shown schematically as
insert in (B)). (B) Shows the same data as (A), normalized to their maximal
value and shifted by their fitted onset times, t0. (C) Distribution of the onset
time t0 (mRNA data shown in blue, pDNA data shown in red). (D)
Distribution of the expression rate kTL · m0. (E) Distribution of the mRNA
degradation rate. The black dashed line shows the Gaussian fit to the
experimental data, whereas the red dashed line is the Gaussian fit to simulated
data (see Supplementary) (F) Distribution of the eGFP decay rate. Dotted lines
represent the Gaussian fit to experimental (black) and simulated (red) data.
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experiments, identical transfection protocols were followed for
mRNA and pDNA transfection using the commercial cationic
lipid agent Lipofectamine2000®.
The FC data shown in Figure 2 were taken 25 hours post-
transfection. The scatterplots with the fluorescence intensity onthe x-axis and the sideward scattering signal on the y-axis show
consistent bimodal populations. Both mRNA and pDNA
mediated transfection exhibit eGFP-expressing cells and cells
that do not express any eGFP. However, for three different cell
types, the fluorescence level of eGFP expressing cells in case of
pDNA mediated expression is more broadly distributed and
shifted towards higher values than the eGFP distribution
appearing in mRNA transfection. This effect is also seen in the
integrated representation, where the distribution of the average
number of eGFP molecules per eGFP expressing cell is shown
(Figure 2, G–I). Here, pDNA transfection is shown in red and
mRNA transfection in blue. Note that for pDNA transfection,
22% (HeLa), 7% (A549), and 28% (MDCKII) of the cells exhibit
eGFP expression levels of 1000 (a.u.) and higher that are not
shown for better clarity. In the last row (Figure 2, J-L), the
percentage of transfected cells are depicted, which is a direct
measure of the transfection efficiencies. We find slightly lower
percentages of transfected cells for mRNA-transfected cells
compared to pDNA-transfected cells except for MDCKII cells,
which feature higher transfection for pDNA vectors.
Single-cell mRNA expression kinetics
The most revealing difference between transfection with
mRNA and pDNA is seen in the single-cell expression kinetics
retrieved from time-lapse studies (Figure 3). Typically, begin-
ning after 1.5 hours of incubation, fluorescence microscopy
movies were taken over 25 hours using automated time-lapse
microscopy. The total fluorescence intensity of each single cell
was followed by image analysis40 and converted into the number
of eGFP molecules per cell (see Supplementary). Figure 3 shows
two typical microscopy images of transfected cells 25 hours
post-transfection (Figure 3, A and B). Bright field and
fluorescence images were overlaid to illustrate the fraction of
transfected cells. Figure 3, C and D show gene expression time-
courses of single cells. To highlight the characteristic differences
in the expression kinetics, we picked three representative traces
each and show them in color. While mRNA-transfected cells
show an early and steady rise to a maximum with a subsequent
decrease, pDNA transfection results in sigmoidal intensity time-
courses with a steady-state level of eGFP expression and random
onset times. In contrast to the ubiquitous early onset of eGFP
expression with mRNA that mainly occurs within 5 hours after
transfection, the onset of eGFP expression after transfection with
pDNA is spread over the range of 2 hours to 20 hours.
Modeling mRNA expression
Since mRNA transgene expression solely involves transla-
tion, quantitative modeling reduces to a simple biochemical
reaction scheme defined by three kinetic rates as shown in
Figure 4, B. The schematic shows a rate equation model for
mRNA expression consisting of translation, mRNA, and eGFP-
degradation. The model is described by the following set of
equations for the changes in the number of eGFP molecules,
G(t), and the number of mRNA molecules, m(t):
d
dt
G ¼ kTL⋅m−β⋅G ð1Þ
Figure 5. Dose–response relation. (A) Percentage of positively transfected
A549 cells as a function of increasing amount of mRNA (0.05/0.1/0.5/1/
2 μg). Squares correspond to FC data. The dashed grey line is a single-
Poisson fit, the black line is a double-Poisson fit according to our stochastic
delivery model. (B) Corresponding fluorescence intensity distributions as
measured by FC (bottom to top with increasing mRNA dose).
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dt
m ¼ −δ⋅m ð2Þ
where kTL denotes the translation rate and δ and β the degradation
rates of mRNA and eGFP, respectively. With t0 being the time of
expression onset and the initial conditions G (t0) = 0 and m
(t0) = m0, the following solution for the number of eGFP
molecules is obtained:
GmRNA tð Þ ¼ kTL⋅m0δ−β ⋅ 1−e
− δ−βð Þ t−t0ð Þ
 
⋅e−β t−t0ð Þ ð3Þ
Applying Eq. 3 to the experimental time-courses, the data are
indeed well fitted. The blue curves in Figure 4, A show
exemplary best fits to single-cell time-courses (from a total of
281 time-courses). There are four free parameters: the onset time
t0, the product of translation (kTL) and initial number of
effectively translated mRNA molecules (m0), as well as mRNA
and protein degradation rates (δ and β). Eq. 3 entails a time-course showing an exponential increase with rate δ-β and a long-
term decay with decay rate β (see Supplementary). Each fit
yields an individual set of parameters. Figure 4, C-F presents the
corresponding distribution of the best-fit parameters, which will
be discussed in the following.
Expression onset time distribution
In Figure 4, C, the onset time of mRNA (blue) is shown in
comparison to the onset time for pDNA transfection (see
Supplementary). The faster transfer of mRNA is clearly
documented in this distribution. In the case of A549 cells
shown here, the onset time distribution after transfection with
mRNA peaks approximately 3 hours after transfection and
hardly shows any delayed expression onset events after 5 hours,
whereas the pDNA onset time distribution is spread over the
interval between 2 and 20 hours post-transfection. The time-
distribution is an indirect, yet quantitative measure for the
transfer time of delivery. As known from microscopy studies,
endosomal uptake already starts 10–30 minutes after
transfection.30,41 Therefore, the measured delay in case of
mRNA transfer must be limited by endosomal escape rates.
Remarkably, mRNA expression onset ceases after 10 hours,
indicating that no more endosomes lyse or (more likely) that
mRNA molecules are degraded in acidic late endosomes. The
broadly distributed onset times for pDNA are associated with
rare nuclear entry events, which are believed to occur
predominately during mitosis.
mRNA degradation rates
Figure 4, E shows the distribution of the mRNA degradation
rate retrieved from fitting single-cell time-courses with the
described model. The average mRNA degradation rate of 0.062/h
(corresponding to an mRNA life time of t1/2 ≈ 11 hours) is in
rough agreement with the literature value of 0.028/h.10 The value
is clearly smaller than the degradation rate of endogenous mRNA
(δ b 0.14/h42), which is consistent with the reportedly higher
stability of ARCA capped mRNA vectors. The distribution of
mRNA degradation is well described by a Gaussian with half-
width 0.024/h. This variability in the degradation rate is on the
order of the so-called “extrinsic noise” in eukaryotes.43 The
values for the degradation of eGFP (with a mean of 0.056/h) are
higher than values that have been reported previously.42,44 In
general, it is noteworthy that the single-cell analysis yields
estimates for δ and β with high accuracy. The Gaussian fit yields
mean values with less than 6% relative error. Knowing the
degradation rates is of great value for the improvement of novel
vectors and capping sequences. Furthermore, the degradation
times are a key to predicting the time-course of expression. In
fact, analysis of Eq. (3) predicts that the maximum of expression
is reached approximately at tmax = 17 h. The time point of half
maximum expression value in the declining late phase of
expression is t1/2 = 45 h. The latter is important because it is a
measure for the duration of the transient mRNA expression. Note
that Eq. 3 also holds for the case δ b β (see Supplementary).
Moreover, the expression rate kTL · m0 and the difference in
the degradation rates (δ-β) both determining the amplitude and
hence the maximal expression levels, are uncorrelated (see
Figure 6. Two-step stochastic mRNA delivery model. (A) Schematic drawing
of the stochastic uptake of lipoplexes by endosomes, lysis of the endosomes,
and release of the mRNA load by lipoplexes. The model reproduces the
dose–response relation shown in Figure 6, A. (B) Fluorescence autocorre-
lation function of lipoplexes showing an average hydrodynamic radius of
Rhydr. = 60 nm. (C) Fluorescence image of fluorescently labeled mRNA
lipoplexes adsorbed to a petri dish at the concentration that was used for time-
lapse transfection experiments (dose: 1 μg/ml mRNA). Image analysis led to
a typical lipoplex density of order 4000/mm2 corresponding to about 4–
8 lipoplexes per cell (intensity scale inverted for clarity, scale bar 25 μm). (D)
Typical A549 cell five hours after transfection with fluorescently labeled
mRNA-lipoplexes (shown in red, scale bar 25 μm). (E) Predicted distribution
of delivered lipoplexes derived from the dose–response relation. (F)
Predicted distribution of delivered mRNA molecules, based on an average
of 350 mRNA molecules per lipoplex. (G) Experimental probability
distribution of expression rates (kTL · m0, black bars) derived from single-
cell data. Blue line indicates best fit of mRNA distribution to the expression
distribution, yielding an approximate translation rate of kTL = 170/h.
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to simulated data are additionally shown. For simulation, we
used the experimentally measured mean degradation rates (see
Supplementary). These fits should represent intrinsic noise only,
which accounts for about 30% of the total noise. The additional
width of the experimental data can be attributed to extrinsic sources
of noise involved in the gene transfer process. The kinetics of
mRNA proves to be generic because different cell types show the
same mRNA expression curves (see Supplementary).
A stochastic delivery model by Numbers
It is generally understood that mRNA as well as pDNA
delivery via artificial, non-viral vectors is stochastic and
dominated by rare processes. In the case of mRNA transfection,
the limiting steps are endosomal uptake, endosomal lysis, and
mRNA release from lipoplexes. Here, we ask the question
whether the measured distribution of expression levels can be
reproduced in a stochastic rate model, where each step is
assumed to be described by a random process with defined
transition probability. The fact that a large fraction of cells does
not express eGFP at all indicates that there is a finite probability
that no nucleic acid is successfully transferred. Figure 5, A
shows the dose–response curve in terms of the percentage of
transfected cells versus the concentration of mRNA in μg RNA
per ml transfection medium. The corresponding distribution of
eGFP expression levels can be seen in Figure 5, B. Data were
taken 25 h after transfection using FC. The number of
transfected cells monotonically increases with mRNA dosage.
It is instructive to describe the transfection process in terms of
number of lipoplexes: Lipoplexes form when cationic lipid
liposomes are complexed with nucleic acid. Each lipoplex
contains a large average number of mRNA molecules (as
discussed below). Hence, the delivery of a single lipoplex results
in a burst of eGFP expression. If lipoplexes were delivered by
overcoming a single barrier, the dose–response function would
be described by a Poisson-like process as represented by the
dashed line in Figure 5, A (see Supplementary). In this case, the
average number of effectively delivered lipoplexes would be
〈C〉SP = 0.5. However, as shown in Figure 5, A, the fraction of
transfected cells can be more closely described by a chain of two
successive Poisson processes. In this case, the response does not
rise up to 100% at large mRNA concentration, which is due to
the fact that the two Poisson processes are sequential. A physical
interpretation of such a chain of events is shown in Figure 6,A: The
scheme shows endosomal uptake of lipoplexes, endosomal lysis,
and mRNA release from lipoplexes. It is assumed that N
endosomes are stochastically loaded with a small number of lipo-
plexes, Leff, and that subsequently a small fraction of endosomes,
Neff, undergoes lysis. These two stochastic steps are modeled as
Poisson processes and determine the number of delivered
lipoplexes, C. If we assume the lipoplex load Leff to be propor-
tional to the mRNA concentration, i.e. Leff = λ⋅cmRNA, we obtain a
two-parameter expression for the dose–response function (see
Figure 5, A and Supplementary). The best fit yields Neff = 0.9 and
λ = 1.1 μg-1, meaning that at the highest dose of 2 μg, an effective
number of Leff = 2.2 lipoplexes are contained per endosome and
that an average of 〈C〉 = Neff⋅Leff = 2 successfully deliveredcomplexes is obtained. To demonstrate that such a surprisingly
small number of effectively delivered lipoplexes is realistic, we
assessed the average number of lipoplexes resting on a single cell in
an experiment. At a dose of 1 μg mRNA and after one hour
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4000/mm2, corresponding to an average of 4–8 lipoplexes per
cell (Figure 6, C). This number is strongly dependent on
incubation time due to the diffusion limited transport of the
lipoplexes. After five hours of incubation, the number of
lipoplexes doubles as seen in Figure 6, D. We can safely assume
that almost all lipoplexes that hit the cell surface will be taken
up by endocytosis over time as reported by others.29,30 How-
ever, not every endosome releases its lipoplex cargo into the
cytosol. We find that a lysis rate of about 25–50% leads to
accordance of the experimental dose–response relation with the
above theoretical estimate.
A single lipoplex contains an average of 〈m〉 = 350 mRNA
molecules. This number is derived knowing the size and packing
density of lipoplexes (see Supplementary). The mRNA lipo-
plexes used here exhibit an average hydrodynamic radius of
60 nm as measured by fluorescence correlation spectroscopy
(FCS) (Figure 6, B). The structure and packing density have
been measured previously using small angle X-ray scattering
(SAXS).45,46 Figure 6, E shows the theoretical distribution of
delivered lipoplexes based on the double-Poisson model and the
mRNA dose that was used for these experiments (1 μg). If this
distribution is multiplied with the number of mRNA molecules
per lipoplex, we obtain the theoretical distribution of mRNA per
cell as shown in Figure 6, F. It is noteworthy that the theoretical
distribution (Figure 6, G, blue curve) is in very satisfying
agreement with the shape of the experimental distribution
(Figure 6, G, black bars) of expression rates. Comparing the
theoretical mRNA distribution with the actually measured
distribution of expression rates, kTL · m0, we find kTL = 170/h.
This translation rate, which emerges from the analysis of single-
cell expression rates, is in the range of independently published
values of translation rates.42Discussion
We studied the expression kinetics of eGFP following
transfection mediated by mRNA and pDNA. While pDNA
complexes have to enter the nucleus, mRNA molecules released
from mRNA lipoplexes can be translated immediately after
endosomal escape. Consequently, mRNA-induced expression is
profoundly earlier and more homogeneously timed than pDNA-
induced expression. This behavior is generic and similar onset
time distributions are observed e.g. for HeLa and MDCKII cells
(data not shown). The high transfection efficiencies for pDNA
transfected cells as compared to mRNA transfected cells might
be a result of size-dependent lipoplex uptake that has been
reported previously.47 We determined the pDNA-lipoplexes to
be about 230 nm in diameter (data not shown), as opposed to
120 nm for mRNA-lipoplexes. The narrow timing of mRNA
expression onset at approximately 3 hours post-transfection is in
agreement with the observed timing found for endosomal uptake
and release in single-particle tracking studies.30,41 Therefore, the
mRNA expression onset distribution might serve as a valuable
indicator for the endosomal release time distribution and could
be useful for the advancement of artificial endosomolytic agents.
Furthermore, our data imply that mRNA expression modelingcan predict the transient course of therapeutic efficacy of mRNA
therapeutics in preclinical studies. For example, the development
of improved capping sequences of mRNA vectors can be carried
out using destabilized eGFP variants. In this case, the protein
level decreases substantially faster and long observation times
causing experimental difficulties can be circumvented (see
Figure S7, Supplementary). Based on kinetic rates obtained in
such studies, the time-course of arbitrary gene products with
longer half-life times can be inferred. In this context, it should be
noted that the half-life of about 12 hours for eGFP determined
from single-cell tracks is shorter than previously reported in
ensemble measurements, which necessarily average over the
somewhat heterogeneous timing of whole populations.42,44 We
also showed that the cell-to-cell variability in the expression
levels is well described by a two-step Poisson process. The two-
step stochastic model is capable of reproducing the measured
dose–response curve consistently with the statistical distribution
of expression rates. However, it is limited to transfection in vitro
and provides only an approximate description of the underlying
delivery cascade. The most important element provided by our
model is the account of quantal delivery of mRNA in form of
lipoplexes, which is in quantitative agreement with the measured
distribution functions. The small number of successfully
delivered lipoplexes per cell is the key to understanding the
stochastic outcome of transfection experiments that inherently
allow a finite number of non-transfected cells. More refined
modeling has to be done to picture the dynamics of transfection
and to reproduce the onset time distribution. Here, computational
representation of size-dependent uptake rates, the nature of
endosome lysis, and intracellular diffusion need to be solved.
Furthermore, computational modeling of extracellular delivery,
mimicking in vivo situations, needs to be advanced to gain
impact on translational medicine.
In our experiments, the single-cell time-courses of mRNA-
mediated transfection showed excellent agreement with the
standard biochemical rate model of translation. Hence, single-
cell analysis enables direct determination of expression rates as
well as decay rates for both mRNA and eGFP with great
accuracy and provides a quantitative foundation for kinetic
studies on mRNA translational regulation as for example RNA
interference. The fact that mRNA transfection exhibits a narrow
time window of delivery is beneficial for kinetic studies. This
advantage should be of practical importance for future time-
resolved studies on siRNA knockdown and RNA constructs for
programmed gene regulatory operations.
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